News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)
KIMYRSA™ Receives Product-Specific J-Code and Transitional Pass-Through Status from CMS
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy
Jisoo Park, a leader in global pharmaceutical business development, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller.
-Single-Dose Antibiotic with One-Hour Infusion, Additional Compatibilities in Normal Saline and D5W, and Lower Infusion Volume-